chronic kidney disease

After breakup with Otsuka, Akebia finds new partner for oral anemia drug in Europe
After breakup with Otsuka, Akebia finds new partner for oral anemia drug in Europe
Fierce Pharma
Akebia Therapeutics
Medice Arzneimittel Pütter
Europe
Australia
Vafseo
chronic kidney disease
Flag link:
Genexine's anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings
Genexine's anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings
Fierce Biotech
Genexine
chronic kidney disease
anemia
Roche
CSL Vifor
Mircera
Flag link:
Bayer study finds communication gap in managing chronic kidney disease in patients with type 2 diabetes
Bayer study finds communication gap in managing chronic kidney disease in patients with type 2 diabetes
Medical Marketing and Media
Bayer
diabetes
chronic kidney disease
healthcare providers
physicians
Flag link:
Akebia's Appeal for Anemia in CKD Drug Delayed Again
Akebia's Appeal for Anemia in CKD Drug Delayed Again
BioSpace
Akebia Therapeutics
vadadustat
chronic kidney disease
Flag link:
GSK's oral anemia drug Jesduvroq scores partial FDA nod after 2 rivals suffered rejections
GSK's oral anemia drug Jesduvroq scores partial FDA nod after 2 rivals suffered rejections
Fierce Pharma
GSK
FDA
daprodustat
Jesduvroq
anemia
chronic kidney disease
Flag link:
FDA grants appeal for Ardelyx chronic kidney disease drug after July 2021 rejection
FDA grants appeal for Ardelyx chronic kidney disease drug after July 2021 rejection
Endpoints
Ardelyx
chronic kidney disease
FDA
tenapanor
Flag link:
Kidney Therapeutics to Halt CKD Progression, Make Late-Stage Push Toward NDA
Kidney Therapeutics to Halt CKD Progression, Make Late-Stage Push Toward NDA
BioSpace
Kidney Therapeutics
chronic kidney disease
clinical trials
Flag link:
In surprise turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions
In surprise turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions
Endpoints
Ardelyx
FDA
chronic kidney disease
tenapanor
Flag link:
Akebia Stands by Anemia in CKD Drug in Dispute Resolution Request
Akebia Stands by Anemia in CKD Drug in Dispute Resolution Request
BioSpace
Akebia Therapeutica
FDA
vadadustat
chronic kidney disease
Flag link:
Tricida eyeing sale, cost-cutting options after failing high-stakes CKD wager
Tricida eyeing sale, cost-cutting options after failing high-stakes CKD wager
Endpoints
Tricida
chronic kidney disease
M&A
Flag link:
ASN to Spotlight Debate around Ardelyx's Embattled CKD Drug
ASN to Spotlight Debate around Ardelyx's Embattled CKD Drug
BioSpace
Ardelyx
FDA
tenapanor
chronic kidney disease
Flag link:
Medicare is using one of its biggest hammers to try to fix the dialysis system: how providers are paid
Medicare is using one of its biggest hammers to try to fix the dialysis system: how providers are paid
Stat
dialysis
chronic kidney disease
Medicare
payers
Flag link:
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
BioSpace
Aria Pharmaceuticals
patents
lupus
idiopathic pulmonary fibrosis
IPH
chronic kidney disease
Flag link:
Positive data on Kerendia in chronic kidney disease and type 2 diabetes
Positive data on Kerendia in chronic kidney disease and type 2 diabetes
Pharma Letter
Bayer
Kerendia
chronic kidney disease
ESCC
Flag link:
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Fierce Biotech
Novartis
Gilenya
kidney disease
chronic kidney disease
Flag link:
ADA: Bayer builds its case for potential kidney disease blockbuster Kerendia
ADA: Bayer builds its case for potential kidney disease blockbuster Kerendia
Fierce Pharma
ADA
diabetes
Bayer
chronic kidney disease
Kerendia
Flag link:
AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection
AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection
Fierce Pharma
AstraZeneca
FibroGen
chronic kidney disease
roxadustat
Flag link:
GSK goes for gold as FDA starts review of daprodustat
GSK goes for gold as FDA starts review of daprodustat
Pharmaforum
GSK
chronic kidney disease
anemia
daprodustat
FDA
Flag link:
FDA rejects Akebia drug, dealing another blow to anemia pills
FDA rejects Akebia drug, dealing another blow to anemia pills
BioPharma Dive
Akebia Therapeutics
vadadustat
FDA
chronic kidney disease
anemia
Flag link:
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
BioSpace
Eli Lilly
Boehringer Ingelheim
clinical trials
chronic kidney disease
empagliflozin
Flag link:

Pages